Sleep
DSIP
Emideltide, delta sleep-inducing peptide
DSIP is a nine-amino-acid peptide first isolated in the 1970s from animals in deep sleep. It is not FDA-approved, and older human sleep studies produced weak or inconsistent results.
Key facts
- Commonly discussed for: sleep quality and insomnia.
- Evidence (C): Human evidence consists of small trials from the 1980s and early 1990s; a double-blind study of 16 chronic insomniacs found weak effects and concluded DSIP was unlikely to be of major therapeutic value.
- FDA status: Not recommended. On July 24, 2026 the PCAC voted 6-7 (1 abstention) against adding emideltide (DSIP) to the 503A Bulks List for opioid withdrawal, insomnia and narcolepsy, the only peptide rejected at that meeting.
- Legitimate access: No clear legal route yet.
- Last reviewed: October 1, 2026.
Read the deep dives
Thinking about DSIP?
Add it to your stack, then bring the list to a licensed provider. They can tell you whether it fits your health picture and what the legitimate options are. Peptiblox never sells peptides or links to sellers. Check the legal status tracker for the latest FDA changes.
Open my stack →Sources
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology, 1992
- A clinical trial with DSIP. Eur Neurol, 1984
- McDermott Will & Schulte: PCAC backs majority of peptides in two-day public meeting (July 2026)
- Federal Register notice of PCAC meeting and uses under review (April 16, 2026)